Study on the Efficacy of Erdafitinib in Patients with Tumors with FGFR Mutations or Fusions This academic report is based on the scientific paper “Phase II Study of Erdafitinib in Patients with Tumors with Fibroblast Growth Factor Receptor Mutations or Fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2,” and introduces the...
Research Background In recent years, Poly ADP-ribose Polymerase (PARP) inhibitors have shown significant efficacy as a key approach to treat hereditary BRCA1/2 mutation cancers. However, their effectiveness on tumors with other homologous recombination deficiency (HRD) gene mutations such as ATM, CDK12, and CHEK2 has been less satisfactory. Hence, ...
Phase II Study of Erdafitinib in Patients with FGFR Amplifications: A Detailed Report Background Dysregulation of Fibroblast Growth Factor Receptor (FGFR) family signaling pathways is widely recognized to be associated with cancer development, progression, and treatment resistance. This study primarily investigates tumors with FGFR1-4 amplification...
Overall Survival and Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Patients Based on PTEN Status Academic Background Prostate cancer is one of the most common malignant tumors among men worldwide and a leading cause of cancer-related deaths. Approximately 10%-20% of prostate cancer patients will develop castration-resistant ...
In the tumor microenvironment (Tumor Microenvironment, TME), Immune Checkpoint Inhibitors (ICIs) targeting PD-1 or PD-L1 enhance the body’s natural ability to eliminate cancer cells by disrupting the inhibitory receptor-ligand interaction. However, even so, critical trials indicate that the response rate for monotherapy is <50%, with a median Progr...
Prognostic Model of Pulmonary High-grade Neuroendocrine Carcinoma: Integrating Genomic Analysis and Poly(ADP-ribose) Polymerase-1 Expression Research Background High-grade neuroendocrine carcinoma (HGNEC) of the lung is a highly aggressive cancer with significant biological complexity. Despite its association with Notch pathway activation and inact...
Ovarian cancer is one of the most common and deadly tumor types in women. In recent years, Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown encouraging clinical results in the treatment of ovarian cancer. Numerous studies have found that patients with homologous recombination deficiency (HRD) benefit more from PARPi treatment. Therefore, ...
Scientific Research Report Background Introduction Breast cancer is the most commonly diagnosed cancer worldwide among both men and women, and it is the leading cause of cancer-related deaths in women. The standard treatment for early-stage breast cancer usually involves surgery and (neo)adjuvant chemotherapy and/or endocrine therapy, aiming to eli...
Clinical Validation of AI-based Interpretation of PD-L1 Tumor Proportion Score in Predicting Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer In the field of tumor treatment and diagnosis, the assessment of PD-L1 (Programmed Death-Ligand 1) Tumor Proportion Score (TPS) is a critical task, especially in predicting the response ...
Using Cell Cycle Risk Score to Predict the Benefit of Radiotherapy Combined with ADT in Newly Diagnosed Prostate Cancer Patients Background Prostate cancer is one of the most common cancers among men globally. In terms of treatment, localized prostate cancer is often treated primarily with radiotherapy (RT). However, the efficacy of RT alone is oft...